期刊文献+

浅谈我国药品安全数据合作伙伴的构想 被引量:4

Ideas on the Project of Drug Safety Data Partner Cooperation in China
下载PDF
导出
摘要 通过介绍美国FDA的哨点行动概况、哨点系统的特点和作用、哨点系统的建设进程等方面内容,分析了哨点系统这种分散数据库形式的主动监测模式对我国开展药品不良反应监测工作的现实意义和启发,尝试提出现阶段我国药品不良反应监测工作发展的基本原则和方向,设想构建以国家药品不良反应监测哨点联盟和数据源合作研究为具体内容的我国药品安全数据合作伙伴项目。 This article introduces the executive summary of sentinel initiative, the sentinel system vision, progress building the sentinel system. Then it analyses the practical meaning and inspiration for ADR monitoring in China by the sentinel system and tries to establish the fundamental principle and developmental trend of ADR monitoring in the current period. This article suggests the project of drug safety data partner cooperation in China, which includes China adverse drug reaction sentinel union and data source cooperation.
出处 《中国药物警戒》 2016年第12期737-739,744,共4页 Chinese Journal of Pharmacovigilance
关键词 哨点系统 主动监测 数据合作伙伴 国家药品不良反应监测哨点联盟 数据源合作研究 sentinel system active surveillance project of drug safety data partner cooperation China adverse drug reaction sentinel union data source cooperation
  • 相关文献

参考文献5

二级参考文献23

  • 1FDA.the Senate and House of Representatives of the United States of America, Food and Drug Administration Amendments Act of 2007, [EB/OL]. 2007-09[2011-01].http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=110 cong_public_laws&docid=f:pub1085. 110.
  • 2FDA Developing the Sentinel System - A National Resource for EvidenceDevelopment [EB/OL]. 2008-03 [2011-01-12]http.//www. fda.gov/Safety/FDAsSentinelInitiative/ucm089474.htm.
  • 3Platt R, Wilson M, Chan K A, et al. The new Sentinel Network -improving the evidence of medical-product safety[J]. N Engl J Med, 2009,361:645-647.
  • 4FDA, The Sentinel Report, National Strategy for Monitoring Medical Product Safety is available at[EB/OL].[ 2008-03[2011-02] http: //www. fda. gov/downloads/S afety/FDAsSentinellnitiative/UCM 124701pdf.
  • 5Brown J S, Holmes J H, Shah K, et al . Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care[J]. Med Care, 2010,48:Suppl:S45-S51.
  • 6Executive Office of the President President' s Council of Advisors on Science and Technology, Realizing the full potential of health information technology to improve healthcare for Americans: the path forward. Washington, DC: Executive Office of the President [EB/OL]. 2010-12[2011 -01].http://www.whitehouse.govlsites/ default/files/microsites/ostp/pcast-health-it-report.pdf.
  • 7Centers for Disease Control and Prevention ( CDC ). Global mea- sles mortality, 2000-2008 [ J ]. MMWR Morb Mortal Wkly Rep, 2009,58(47) :1321-1326.
  • 8Bonhoeffer J, Bentsi-Enchill A, Chen RT, et al, Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies [ J ]. Vaccine, 2009,27 ( 16 ) : 2282-2288.
  • 9WHO, UNICEF, World Bank. State of the World' s Vaccines and Immunization, Third edition. [ EB/OL]. [2009]. World Health Organization, http://whqlibdoc, who. int/pub|ications/2009/ 9789241563864_eng. pdf.
  • 10Gurwitz D, Pirmohamed M. Pharmacogenomics: the importance of accurate phenotypes [ J ]. Pharmacogenomics, 2010,11 (4) :469- 470.

共引文献26

同被引文献31

引证文献4

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部